Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study

Cancer

Volumn 120, Issue 2, 2014, Pages 190-196

  Moreira, Daniel M ^a   Nickel, J Curtis ^b   Gerber, Leah ^c,d   Muller, Roberto L ^c,d   Andriole, Gerald L ^e   Castro Santamaria, Ramiro ^f   Freedland, Stephen J ^c,d  

^a The Arthur Smith Institute for Urology   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

inflammation; prostate cancer; prostate specific antigen; prostatic neoplasm; prostatitis

Indexed keywords

DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFECT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN BLOOD LEVEL; REPEAT PROCEDURE; RETROSPECTIVE STUDY; RISK REDUCTION; SENSITIVITY ANALYSIS;

EID: 84891840537     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28349     Document Type: Article

References (27)

1. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-545.
2. Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ,. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013; 49: 938-945.
3. Shebl FM, Sakoda LC, Black A, et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer. 2012; 107: 207-214.
4. Rosenblatt KA, Wicklund KG, Stanford JL,. Sexual factors and the risk of prostate cancer. Am J Epidemiol. 2001; 153: 1152-1158.
5. Sarma AV, McLaughlin JC, Wallner LP, et al. Sexual behavior, sexually transmitted diseases and prostatitis: the risk of prostate cancer in black men. J Urol. 2006; 176: 1108-1113.
6. Dennis LK, Lynch CF, Torner JC,. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002; 60: 78-83.
7. Cheng I, Witte JS, Jacobsen SJ, et al. Prostatitis, sexually transmitted diseases, and prostate cancer: the California Men's Health Study. PLoS One. 2010; 5: e8736.
8. Sutcliffe S, Giovannucci E, De Marzo AM, Leitzmann MF, Willett WC, Platz EA,. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2160-2166.
9. Sutcliffe S, Platz EA,. Inflammation and prostate cancer: a focus on infections. Curr Urol Rep. 2008; 9: 243-249.
10. Platz EA, De Marzo AM,. Epidemiology of inflammation and prostate cancer. J Urol. 2004; 171 (2 pt 2): S36-S40.
11. Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, Fujisawao M,. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL. Urology. 2008; 72: 1194-1197.
12. Fujita K, Hosomi M, Tanigawa G, Okumi M, Fushimi H, Yamaguchi S,. Prostatic inflammation detected in initial biopsy specimens and urinary pyuria are predictors of negative repeat prostate biopsy. J Urol. 2011; 185: 1722-1727.
13. Okada K, Kojima M, Naya Y, et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology. 2000; 55: 892-898.
14. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010; 362: 1192-1202.
15. Andriole GL, Kirby R,. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol. 2003; 44: 82-88.
16. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS,. Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol. 2007; 178 (3 pt 1): 896-900; discussion 900-991.
17. Wu C, Moreira DM, Gerber L, Rittmaster RS, Andriole GL, Freedland SJ,. Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis. 2011; 14: 326-331.
18. Pepe P, Aragona F,. Does an inflammatory pattern at primary biopsy suggest a lower risk for prostate cancer at repeated saturation prostate biopsy? Urol Int. 2011; 87: 171-174.
19. Gui-Zhong L, Libo M, Guanglin H, Jianwei W,. The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis. Int Urol Nephrol. 2011; 43: 295-301.
20. Sfanos KS, De Marzo AM,. Prostate cancer and inflammation: the evidence. Histopathology. 2012; 60: 199-215.
21. Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E,. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol. 2000; 37: 404-412.
22. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS,. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008; 54: 1379-1384.
23. Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ,. Prostatitis as a risk factor for prostate cancer. Epidemiology. 2004; 15: 93-99.
24. Gann PH, Fought A, Deaton R, Catalona WJ, Vonesh E,. Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol. 2010; 28: 1714-1720.
25. Kryvenko ON, Jankowski M, Chitale DA, et al. Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. Mod Pathol. 2012; 25: 1023-1032.
26. Finn OJ,. Cancer immunology. N Engl J Med. 2008; 358: 2704-2715.
27. Kandirali E, Boran C, Serin E, Semercioz A, Metin A,. Association of extent and aggressiveness of inflammation with serum PSA levels and PSA density in asymptomatic patients. Urology. 2007; 70: 743-747.